Effect of repeated dosing on the pharmacokinetics of oral fluconazole in bone marrow transplant patients

Journal of Clinical Pharmacology

Volumn 37, Issue 11, 1997, Pages 1031-1037

  El Yazigi, Adnan ^a,b   Ellis, Michael ^a   Ernst, Peter ^a   Hussein, Ajaa ^a   Baillie, Fiona J ^b  

^a Research Centre   (Saudi Arabia)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUCONAZOLE; MICONAZOLE;

ADOLESCENT; ADULT; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ELIMINATION; FEMALE; HUMAN; KIDNEY CLEARANCE; MALE; MEAN RESIDENCE TIME; NEUTROPENIA; ORAL DRUG ADMINISTRATION; STEADY STATE; URINALYSIS; URINARY EXCRETION;

EID: 0030734528     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04284.x     Document Type: Article

References (19)

1. Goodman JL, PJ Winston RA. Greenfield et al: A controlled study of fluconazole to prevent fungal infection in patients unde'rgoing bone marrow transplantation. NEJM 1992;326:845-851.
2. Ellis ME, H Clink, P Ernst, MA Halim, A Padmos, D Spence et al: Controlled study of fluconazole in the prevention of fungal infections among neutropenic patients with haematological malignancies and bone marrow transplant recipients. Eurf Clin Micro Infect Dis 1994;13:3-11.
3. Winston DJ, PH Chandrasekar, HM Lazarus, JL Goodman, JS Silber, H Horowitz, et al: Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Int Med 1993;118:495-503.
4. Wingard JR, WG Merz, MG Rinaldi, TR Johnson, JE Karp, R Saralilncrease in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. Af£7Ml991;325:1274-1277.
5. Ripa S, L Ferrante, M Prenna: Pharmacokinetics of fluconazole in normal volunteers. Chemotherapy 1993;39:6-12.
6. Fischman AJ, NM Alpert, E Livni, S Ray, I Sinclair, RJ Callahan: Correia JA. Webb D. Strauss HW. Rubin RH. Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography. Antimicrob Agents Chemother 1993; 37:1270-1277.
7. Shiba K, A Saito, T Miyahara: Safety and pharmacokinetics of single oral and intravenous doses of fluconazole in healthy subjects. Clin Ther 1990:12:206-215.
8. Nakashima M: The clinical study of fluconazole against pulmonary mycosis. Effects of fluconazole on cryplococcocis and asporgillosis and its pharmacokinetics in patients. Jap J Antibiot 1989:42:127-137.
9. Inagaki K, J Takagi, E Lor, MP Okamoto, MA Gill: Détermina-lion of fluconazole in human scrum by solid-phase extraction and reversed-phase high-performance liquid chromatography. Ther DrugMonit 1992; 14:306-311.
10. Gibaldi M, Perrier D: Pharmacokinetics. New York: Marcel Dekker, 1975.
11. Brammer KW, Farrow PR, Faulkner JK: Pharmacokinetics and tissue penetration of fluconazole in humans. fiev Infect Dis 1990;12 (Suppl) 3:S318-S26.
12. Koks CH, Meenhorst PL, Hillebrand MJ, Bull A, Beijnen JH: Pharmacokinetics of fluconazole in saliva and plasma after administration of an oral suspension and capsules. Antimicrobl Agents Chemother 1996;40:1935-1937.
13. Foulds G, Brennan DR, Wajszczuk C, Catanzaro A, Garg DC, Knopf W, Rinaldi M, Weidler DJ: Fluconazole penetration into cerebrospinal fluid in humans. J Clin Pharmacol 1988; 28:363366.
14. Grant SM, Clissold SP: Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990;39:877916.
15. Zimmermann T, RA Yeates, KD Riedel, P Lach, H Laufen: The influence of gastric pH on the pharmacokinetics of fluconazole: the effect of omeprazole. Inter J Clin Pharmacol Ther 1994:32:491-494.
16. Yeates, RA, M Ruhnke, G Pfaff, A Hartmann, M Trautmann, E Sarnow: The pharmacokinetics of fluconazole after a single intravenous dose in AIDS patients. Br J Clin Pharmacol 1994;38(1):77-79.
17. Ruhnke M, RA Yeates, G Pfaff, E Sarnow, A Hartmann, M Trautmann: Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis, J Antimicrob Chemother 1995:35:641647.
18. Toon S, CE Ross, R Gokal, M Rowland: An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole. Br J Clin Pharmacol 1990; 29:221-226.
19. Milliken S, R Powles, A Jones, G Helenglass: Pharmacokinetics of oral fluconazole in autologous bone marrow transplantation recipients given TBI and high-dose melphalan. Transplant Proc 1989;21:3067.